Article
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Cancer discovery - 2 Dec 2022
Bosse Kristopher R, Giudice Anna Maria, Lane Maria V, McIntyre Brendan, Schürch Patrick M, Pascual-Pasto Guillem, Buongervino Samantha N, Suresh Sriyaa, Fitzsimmons Alana, Hyman Adam, Gemino-Borromeo Maria, Saggio Jennifer, Berko Esther R, Daniels Alexander A, Stundon Jennifer, Friedrichsen Megan, Liu Xin, Margolis Matthew L, Li Marilyn M, Tierno Marni Brisson, Oxnard Geoffrey R, Maris John M, Mossé Yael P
Abstract excerpt
Neuroblastoma evolution, heterogeneity, and resistance remain inadequately defined, suggesting a role for circulating tumor DNA (ctDNA) sequencing. To define the utility of ctDNA profiling in neuroblastoma, 167 blood samples from 48 high-risk patients were evaluated for ctDNA using comprehensive genomic profiling. At least one pathogenic genomic alteration was identified in 56% of samples and 73% of evaluable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.